MARK BROOKS: Open Payments
NPI 1003834599 · HUMBLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,573 in 68 payments from 28 companies in 2025. Trend: 2023 $1,057 · 2024 $902 · 2025 $1,573
Food & beverage: $1,573
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 6 | $169 |
| Neurocrine BioSciences, Inc. | 4 | $119 |
| ABBVIE INC. | 6 | $110 |
| Regeneron Healthcare Solutions, Inc. | 5 | $97 |
| Madrigal Pharmaceuticals | 3 | $94 |
| Janssen Biotech, Inc. | 4 | $79 |
| GENZYME CORPORATION | 4 | $78 |
| Galderma Laboratories, L.P. | 3 | $71 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $71 |
| Insulet Corporation | 3 | $70 |
Products named: DUPIXENT, Bimzelx, CRENESSITY, REZDIFFRA, SKYRIZI, TREMFYA, Omnipod, Kerendia.
Industry payments across TX — which companies pay providers there.
